Immunophage Biomedical Co. Ltd. has synthesized macrophage migration inhibitory factor (MIF) inhibitors reported to be useful for the treatment of cancer and inflammation.
Exelixis Inc. has disclosed membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.
Mira Pharmaceuticals Inc. has released new preclinical study results for its oral ketamine analogue, Ketamir-2, which is under investigation for potential to treat neurological and neuropsychiatric disorders, including depression, treatment-resistant depression and post-traumatic stress disorder.
Researchers from Chongqing Medical University and affiliated organizations reported findings from studies they performed to assess the role of zinc-finger protein 334 (ZNF334) in cervical cancer.
Researchers from CONICET and affiliated organizations presented the discovery of novel llama-derived single-chain antibody fragments (VHHs) specific for type A influenza virus.
Researchers from Shanxi Medical University presented data from a study that aimed to assess the effects of delayed treatment with G protein-coupled receptor 65 (GPR65) agonist BTB-09089 on neurorestoration following ischemic stroke in mice.
Scisparc Ltd.’s Mitocarex Bio Ltd. venture has validated the potential significant involvement of its target SLC25 carrier protein, using non-small-cell lung cancer (NSCLC) cells with diverse genetic backgrounds. Mitocarex used genetic manipulations and 3D spheroid systems, mimicking the main features of human solid tumors, to demonstrate the discovery.
Researchers from Shandong University and affiliated organizations reported the discovery and preclinical characterization of novel 68Ga-labeled PSMA-targeting tracers for the diagnosis of prostate cancer.
RSS
